Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.CERC · Entity 4936 | Director | June 30, 2017 | July 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 30, 2017 · Filed July 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2027-06-29 | Direct | 8,357 |
Reported balance
After 2017-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-30 · Grant · Acquired 8,357 · Balance 8,357 F1: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2017 Filed Jul 31, 2017 13:31 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,357 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001562180-17-002529 · primarydocument.xml · derivative · entry 1 Aasen Thomas H · CIK 0001291969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,357 Underlying: Common Stock · 8,357 shares Expires 2027-06-29 F1 · derivative.exercise_date: The stock options will vest in full on June 30, 2018, subject to the grantees continued service on such vesting date. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 14:15 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,764 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001562180-17-001404 · primarydocument.xml · derivative · entry 1 Aasen Thomas H · CIK 0001291969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,528 Underlying: Common Stock · 10,764 shares Expires 2027-03-30 Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 13:53 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,764 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001562180-17-001401 · primarydocument.xml · derivative · entry 1 Aasen Thomas H · CIK 0001291969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,764 Underlying: Common Stock · 10,764 shares Expires 2027-03-30 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 19:54 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,060 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001562180-17-000138 · primarydocument.xml · derivative · entry 1 Aasen Thomas H · CIK 0001291969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,060 Underlying: Common Stock · 8,060 shares Expires 2026-12-30 F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on December 31, 2016. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 19:09 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,883 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001179110-16-030157 · edgar.xml · derivative · entry 1 Aasen Thomas H · CIK 0001291969 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883 Underlying: Common Stock · 1,883 shares Expires 2026-09-29 F1 · derivative.exercise_date: The stock options immediately vested and became exercisable in full upon grant on September 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.